Intravenous Delivery of Targeted Liposomes to Amyloid-β Pathology in APP/PSEN1 Transgenic Mice

Eric A. Tanifum1,2, Indrani Dasgupta2*, Mayank Srivastava1,2, Rohan C. Bhavane1,2, Li Sun3, John Berridge3, Hoda Pourgarzham3, Rashmi Kamath1, Gabriela Espinosa1, Stephen C. Cook5, Jason L. Erikson2*, Ananth Annpragada1,2,4*

1 Pediatric Radiology, Texas Children’s Hospital, Houston, Texas, United States of America, 2 School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America, 3 Department of Pharmacology and Pharmaceutical Sciences, University of Houston, Houston, Texas, United States of America, 4 Department of Radiology, Baylor College of Medicine, Houston, Texas, United States of America, 5 Fieldstone Partners, Houston, Texas, United States of America

Abstract

Extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles constitute the major neuropathological hallmarks of Alzheimer’s disease (AD). It is now apparent that parenchymal Aβ plaque deposition precedes behavioral signs of disease by several years. The development of agents that can target these plaques may be useful as diagnostic or therapeutic tools. In this study, we synthesized an Aβ-targeted lipid conjugate, incorporated it in stealth liposomal nanoparticles and tested their ability to bind amyloid plaque deposits in an AD mouse model. The results show that the particles maintain binding profiles to synthetic Aβ aggregates comparable to the free ligand, and selectively bind Aβ plaque deposits in brain tissue sections of an AD mouse model (APP/PSEN1 transgenic mice) with high efficiency. When administered intravenously, these long circulating nanoparticles appear to cross the blood-brain barrier and bind to Aβ plaque deposits, labeling parenchymal amyloid deposits and vascular amyloid characteristic of cerebral amyloid angiopathy.

Introduction

Alzheimer’s disease (AD) is the most common form of dementia in people over the age of 65 and the sixth leading cause of death in the United States. Over 5.4 million Americans suffer from the disease with many more at risk. In 2012, costs associated with care of AD patients were estimated at US$200 billion, not including contributions from unpaid caregivers valued at over US$210 billion [1]. Globally, an estimated 35.6 million people suffer from the disease with an estimated economic impact of US$604 billion [1]. Globally, an estimated 35.6 million people suffer from the disease with an estimated economic impact of US$604 billion [1]. The global prevalence is projected to increase to 115 million by 2050 [2].

The diagnosis of probable AD in living patients currently employs a battery of neuropsychological tests, the most common of which is the mini mental state exam (MMSE) [3], and a definitive diagnosis requires a post-mortem assessment. The best treatment options currently available only address the symptoms, and not the underlying disease.

Extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles constitute the major neuropathological hallmarks of AD. Current empirical data suggest that Aβ deposition is associated with the earliest stages of AD [4,5] and may peak 10 to 20 years prior to Mild Cognitive Impairment (MCI) [6], the earliest clinical manifestation of the disease. There is a significant interest in being able to image potential biomarkers in living patients as a method for both predicting Alzheimer’s disease risk and monitoring progression [7]. Methods to quantify Aβ burden by positron emission tomography (PET) using18F and 11C-based radiolabeled ligands have been actively developed in recent years [8], with the 18F based stilbene (Amyvid) [9] recently receiving FDA approval for use in patients. Although this technique has high sensitivity, PET imaging has significant drawbacks that limit reliability of results, easy access, and availability to patients. For instance, PET agents have relatively coarse spatial resolution with voxels a few millimeters in size [10]. Cerebral amyloid angiopathy (CAA) and the Aβ lesions observed in AD transgenic mice, normal aged humans, and AD patients are microns in diameter, morphologically distinct (mostly diffuse, neuritic, and compact plaques) [11,12,13], and not all relevant to definite AD diagnosis [14]. However, all are capable of binding and generating a positive signal from the current PET agents [15,16,17]. Preparation of PET agents requires radiochemistry,

Citation: Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, et al. (2012) Intravenous Delivery of Targeted Liposomes to Amyloid-β Pathology in APP/PSEN1 Transgenic Mice. PLoS ONE 7(10): e48515. doi:10.1371/journal.pone.0048515

Editor: Karl Herholz, University of Manchester, United Kingdom

Received May 15, 2012; Accepted September 26, 2012; Published October 31, 2012

Copyright: © 2012 Tanifum et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported with funds from the Cure Alzheimer’s Fund (A.A. and J.L.E.), the Alliance for Nanohealth (A.A. and J.L.E.), the National Institutes of Health (J.E., 1R15AG039008-01) and the Alzheimer’s Association (J.L.E., NIRG-08-92033). NMR work at the MD Anderson Cancer Center was supported by NCI Cancer Center Support grant CA016672. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: AA, JLE, SCC, EAT, ID and MS own stock in Alzeca Biosciences LLC. SCC is employed by Fieldstone Partners, a venture firm that also holds stock in Alzeca Biosciences LLC. Alzeca has no products at this time, but seeks to develop imaging agents for Alzheimers Disease diagnosis and tracking. Alzeca has licensed technology co-developed by the authors of this paper, but no patents have issued yet. This does not alter the authors’ adherence to all the PLOS ONE policies of sharing data and materials.

* E-mail: jeriksen@central.uh.edu (JLE); avannapri@texaschildrens.org (AA)

Current address: Department of Anatomy & Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
an expensive process. The radionuclides currently acceptable for medical use have short half-lives (\(^{18}\text{F} \sim 110\) min, \(^{11}\text{C} \sim 20\) min), limiting imaging time in patients, and the imaging centers that can access the probes. Consequently, advances in diagnostic technology that may improve the quality, resolution, and accessibility of agents that can quantify \(\text{A}\beta\) in living patients are highly desirable.

In normal individuals, macromolecules and nanoparticles do not pass from the blood to the brain parenchyma. The tightly packed endothelial cell lining of the cerebral vasculature, called the blood-brain barrier (BBB) is responsible for this exclusion, and is also the root cause of low drug delivery efficiency to the brain via the vascular route. In AD, however, there are several pathophysiological changes associated with \(\text{A}\beta\) deposition that are strongly suggestive of a compromised BBB. These include microvascular poration, a reduction in microvascular density, an increased number of fragmented vessels, and endothelial wall degeneration [18,19,20,21]. Proteins normally sequestered within the blood pool have been reported in the parenchyma. Immunohistochemistry studies in both humans and AD mouse models show elevated levels of plasma-derived proteins such as prothrombin and albumin in vessel walls and in association with parenchymal plaques [22]. In addition to these functional observations of a compromised BBB, there have been direct observations of BBB disruption: Meyer and coworkers demonstrated using Scanning Electron Microscopy, the presence of truncated microvessels and holes with sizes ranging between 0.03 to 3.5 mm\(^2\) in the dense cortical vasculature in aged APP23 transgenic mice along with significant \(\text{A}\beta\) deposits [23]. The accumulation of plaques around vessel walls can result in local inflammatory responses, further weakening the integrity of the neurovasculature [21,24,25]. In a recent study, Biron and coworkers [26] showed that amyloidogenesis may promote extensive neoangiogenesis, leading to increased vascular permeability and subsequent hypervascularization in brain tissue samples from both a transgenic AD mouse model and human patients.

In light of the pathophysiological and vascular changes associated with AD, we hypothesized that long-circulating nanocarriers such as stealth liposomes could passively extravasate to the abluminal side of the neurovasculature by a mechanism similar to the enhanced permeation and retention effect observed in tumors and inflamed tissue [27]. Following extravasation, the particles should subsequently enter the perivascular drainage pathway by which interstitial fluid and solutes are cleared from the brain [28,29,30,31,32], and the seeding site for \(\text{A}\beta\) plaque deposition in CAA [33,34,35].

We have previously demonstrated the use of contrast agents encapsulated in liposomes for both computed tomography (CT) [36], and magnetic resonance imaging (MRI) [37], with resolution \sim 50\) microns. Signal strength is also enhanced in the process: the liposomes encapsulate \sim 10\) contrast agent molecules, and each liposome can bind one molecular target, thus offering a 10\(^3\) signal enhancement factor over a single molecule. However, this is dependent on the ability of the liposomes to reach the target. In this study, we therefore tested whether liposomes targeted to amyloid plaques would be able to reach, and bind to, the plaques following i.v. injection. We prepared an \(\text{A}\beta\)-targeting fluorescent lipid conjugate, 1,2-distearyl-sn-glycero-3-phosphocholine (DPPC), cholesterol, 1,2-distearyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPG) with succinimidyl ester and DSPE-PEG3400-COOH under carbodiimide conditions, as the hydrochloride salt. Conjugation to the lipid-PEG moiety proceed by reacting 13 and DSPE-PEG3400-COOH under carbodiimide conditions to afford 1. All products were characterized by \(^1\)H and \(^{13}\)C NMR, and MALDI mass spectrometry as described in the Methods section.

Preparation and Characterization of Targeted Liposomes

The synthesis of the fluorescent lipid conjugate DSPE-PEG3400-\(\text{NO}_4\) (1), allowed for passive incorporation of the targeting ligand on the surface of the liposomes. A lipid mixture (50 m\(^\text{M}\)) consisting of 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), cholesterol, 1,2-distearyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPG), and the conjugate (1), in a 56.5:40.0:3.0:0.5 molar ratio respectively was dissolved in ethanol. This mixture was hydrated in a histidine (10 m\(^\text{M}\)/saline (150 m\(^\text{M}\)) buffer (pH 7.5) to obtain large, multilamellar vesicles, which were down-sized by sequential extrusion, at 65°C. This approach results in approximately 1:1 distribution of the conjugate 1, between the outer and inner bilayers. Dynamic light scattering (DLS), the traditional method for liposomal particle size determination was ineffective because the strong fluorescence of the \(\text{NO}_4\) interfered with the scattering measurement. Negative stain transmission electron microscopy (TEM) showed a mean diameter of about 150 nm (see supporting information) and liposomes prepared under identical conditions without the \(\text{NO}_4\) ligand exhibited a DLS-based particle size consistent with the TEM measurement. Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES) analysis of the phosphorus content indicated a final lipid concentration of 35.5 m\(^\text{M}\). At this lipid concentration and particle size, an estimated 500 targeting lipids are expected on the surface of each individual liposome. \(\text{NO}_4\) targeted liposomes...
encapsulating Rhodamine were prepared by identical methods, except the hydration mixture included 10 mM Rhodamine, and the preparation was conducted under reduced light levels. The stability of each preparation in plasma was assessed as described in the Supplemental Information section (S18), and showed no significant leak.

**Binding of Targeted Liposomes to Synthetic Aβ Fibrils**

Data demonstrating the in vitro binding of targeted liposomes to Aβ aggregates are presented in Figure 3. The incubation of a fixed concentration of synthetic Aβ(1-40) fibrils (20 μM) with increasing concentrations of liposome-XO4 suspensions (effective XO4 concentration from 0 to 2 μM) or free XO4 showed a corresponding increase in binding, saturating above 0.25 μM for the targeted liposomes and 0.4 μM for the free XO4 (Figure 3A). These results demonstrate that the coupling of XO4 to liposomes does not significantly affect its ability to interact with Aβ fibrils. Furthermore, the non-fluorescent Chrysamine-G (CG) effectively competes with both liposomal XO4 as well as free XO4 for binding to the Aβ fibrils (Figure 3B).

**Binding of Liposomal XO4 to Aβ Deposits in AD Mouse Brain Tissue**

Data showing the ability of targeted nanoparticles to selectively bind Aβ plaques in brain tissue sections of APP/PSEN1 mice are shown in Figure 4. Slides from the non-transgenic control mice (A, B) showed no visible fluorescent spots. In the transgenic mouse brain sections however, clear, bright fluorescent spots were observed both in the cortex (C) and hippocampus (D).

The particles were further tested against CG competition to confirm their specificity in binding Aβ plaque deposits in brain tissue. Figure 5 shows the results of this study, which indicate a decrease in fluorescence intensity and the number of labeled plaques with increasing concentration of CG. This parallels the results obtained from competitive binding of the particles and CG to synthetic Aβ fibrils (Figure 3B), further suggesting that the observed fluorescence on the treated tissues is due to specific binding of particles to Aβ plaque deposits. Taken together with the observed loss of fluorescence from fibrils incubated with the particles and increasing concentrations of CG (Figure 3B), the data are consistent with the targeted liposomes maintaining affinity and selective binding to Aβ aggregates.

**Intravenous delivery of targeted liposomes to cortical and hippocampal plaques in APP/PSEN1 transgenic mice.** The targeted liposomes were administered to 7 and 12 month old APP/PSEN1 mice by tail vain injection to test the hypothesis that they would cross the BBB, enter the perivascular drainage system, and anchor to Aβ plaque deposits. Seventy-two hours following injection, the mice were sacrificed, and their brains sectioned for fluorescence microscopy. Optically stitched images from these sections show visible amyloid plaques in the hippocampus (blue arrows) and cortex (red arrows) in both the 7 month old (Figure 6A) and the 12 month old (Figure 6B) mice. There is a conspicuous increase in the number of plaques per unit area from the 7 month to the 12 month old mice. No distinct labeling of any kind was observed when non-transgenic mice were injected with the nanoparticles, or when untargeted liposomes were injected as observed in the in vitro experiments.

Images from 12 month old mice (Figure 7) reveal that the particles appear to bind amyloid-β deposits across the entire brain. Figure 7A shows the olfactory bulb, 7B the septo- striatum, 7C the septo-diencephalic region, 7D the caudal diencephalon and 7E the rostral diencephalon. In each section, plaques bound by nanoparticles are clearly visible as punctate structures suggesting that the targeted nanoparticles label plaque deposits across the entire brain. Vascular amyloid deposits characteristic of CAA are also clearly bound by the agent. Figure 8 shows an example of CAA in 12 month old APP/PSEN1 mice, labeled by the targeted liposomes. This mouse model is known to exhibit clear signs of CAA at this age, particularly in superficial vessels in the pia mater.

**In vitro immunofluorescence study of treated mouse brain sections to confirm particle localization on amyloid plaques.** In vitro staining of brain tissue sections from the treated mice using two different anti Aβ antibodies (DE2B4 and 4G8) allowed us to confirm localization of the injected particles against Aβ plaque deposits. The DE2B4 antibody is raised against aa1-17 and 4G8 is raised against aa17-24 of the Aβ protein. As shown in Figure 9, nanoparticle-labeled plaques (D and J) represented by the red signal, show co-localization with DE2B4 (E) and 4G8 (K) in their respective composite images (F and L). Negative controls (B and H) did not show any correlated staining. Graphs M and N show the Pearson’s correlation coefficient (PCC) between the antibody signal and the nanoparticle XO4 signal for each focal plaque.

**Co-localization of liposome contents with targeting ligand confirming intact trafficking of liposomes to the amyloid plaques.** Rhodamine was encapsulated into XO4-targeted liposomes by the passive loading method, at a concentration of 10 mM. 72 hours after intravenous injection in mice, the animals were sacrificed; the brains fixed and imaged using a DAPI filter set for the XO4 and a TRITC filter set for the Rhodamine. Figure 10 shows representative images from this experiment.

---

Figure 1. Aβ-Targeted stealth liposome. DSPE-mPEG-2000 lipid conjugate provides stealth properties by preventing facile opsonization and clearance of the particle. DSPE-PEG3400-XO4 conjugate imparts Aβ-targeting properties. *Average number of ethylene glycol units = 75. **Average number of ethylene glycol units = 45.
doi:10.1371/journal.pone.0048515.g001
Discussion

A number of amyloid-beta binding agents have been developed in recent years. Aβ aggregates have multiple binding sites for structurally diverse small molecule ligands [42]. The most prominent of these include Congo red, Chrysamine G (CG), Thioflavin T and their respective derivatives [43]. Some have also been shown to bind to multiple sites on Aβ fibrils albeit with different affinities [44]. Congo red and CG derivatives (including XO4) compete for the same binding pockets while Thioflavin T derivatives compete for separate distinct sites [38,42,43]. XO4 was selected as the targeting ligand for this study because of its high...
affinity and specificity to Aβ aggregates associated with AD. It is symmetrical in shape and its simple stilbene derivatives such as SB-15 [45] maintain high binding affinity to Aβ plaques. This suggested that tethering a linker from either end of the molecule would not adversely affect its binding properties to Aβ aggregates. PEGylation has been shown to have no negative effect on the binding of other Aβ ligands [46]. So the 3-unit PEG linker 3, was employed to link the ligand to the lipid-PEG moiety. Finally, the intrinsically high fluorescence of the conjugate enabled tracking of the location of particles.

The binding profiles of free XO4 and the particles to synthetic Aβ fibrils (Figure 3A) appear to be similar. Both show an increase in fluorescence units with a corresponding ligand concentration. However, there is an apparent higher retention of the fluorescent species by fibrils treated with the nanoparticles compared to the corresponding treatment with free XO4. This can be attributed to the fact that each particle bears over 500 XO4 surface ligands, and just one of these may be bound to enable retention of the particle on the fibril. Yet all of these contribute to the observed fluorescence. It is also apparent from the data that liposomal binding appears to saturate at a lower concentration (~2.5 μM) than the free XO4 (~4 μM). This is consistent with steric hindrance. XO4 is not expected to suffer from this hindrance at these concentrations due to the small size of the molecule compared to the nanoparticle. These binding properties of the particles versus free XO4 are corroborated by results from the competition experiments with Chrysamine G (Figure 3B). These show a consistent loss of XO4 fluorescence with increasing concentration of CG albeit with an apparent greater loss by the particles compared to the free XO4. The consistent drop in measured XO4 fluorescence with increasing concentration of CG suggests that both the liposomal XO4 and free XO4 ligands bind to the same site (i.e., the CG site). This further suggests that XO4 binding ability is unchanged by conjugation to the DSPE-PEG anchor. Taken together with the observed loss of fluorescence from plaque-laden brain tissue sections incubated with the particles and increasing concentrations of CG (Figure 5), these results demonstrate that the targeted liposomes maintain in vitro affinity and selective binding to Aβ aggregates.

Confocal microscope images from tissue sections across the entire brains of treated mice (Figure 7) suggest that the targeted nanoparticles effectively label plaque deposits and CAA (Figure 8). In co-localization studies, the antibodies stain a wider range around each focal plaque labeled by the particles. This is expected since the antibody labels Aβ peptides while the XO4 only labels aggregates containing prominent beta-sheet structures associated with dense core plaques and CAA. Figure 9 shows the results of counterstaining the brain sections from the treated mice with amyloid antibodies DE2B4 and 4G8. The co-localization of the immunoractive locations within the images to the XO4 locations is quantified using the Pearson’s Correlation coefficient calculated in tessellated subdomains each containing a focal XO4 signal cluster. When compared to control sections with no amyloid antibody treatment, the significant increase in PCC in the antibody treated specimens confirms the avid co-localization of the two signals. However, the moderate values for the PCC (<0.5) suggest the presence of antibody staining away from the focal XO4 labeled plaques, as well as diffuse tissue background signal in the XO4 channel away from the antibody signal. Examination of the images in Figure 9 suggests the reasons for this. While virtually all the XO4 labeled locations also exhibit antibody signal, there is diffuse antibody staining at locations with no XO4 signal. This is consistent with the affinity of the antibody to oligomeric and even monomeric Aβ, where XO4 as a β-sheet binder is not expected to bind. On the other hand, practically all the immunoreactive dense-core plaques appear to have XO4 signal, suggesting a near universal labeling of focal plaque pathology at the administered lipid dose, but there is diffuse XO4 signal across the tissue, both in the treated and control specimens. The diffuse XO4 signal is therefore attributable to tissue background. The co-localization of
XO4 and antibody signal is intriguing, but conceivable, given that, according to the Aβ clearance hypothesis, Aβ accumulates in the AD brain as a result of an imbalance between its production and clearance [47]. Aβ is either cleared from the brain by receptor-mediated transcytosis across the BBB into circulation [48] or via a perivascular pathway. Perivascular clearance has been suggested to be the same pathway by which other macromolecules and solutes are cleared from the brain [28,29,30,31,32], and represents a mechanism allowing for Aβ plaque seeding and deposition, as observed in CAA [5]. It is possible that once across the BBB, the

Figure 4. Selective detection of plaque deposits in brain sections of 7 month old APP/PSEN1 mice. Coronal sections (30 μm thick) from non-transgenic and young mice (controls), and 7 month old APP/PSEN1 transgenic mice were incubated in a 3 mM solution of targeted liposomes (effective XO4 concentration = 15 μM) at room temperature, followed by washing with (PBS) to remove unbound liposomes. The stained tissues were then mounted with Vectashield mounting media and viewed under a confocal microscope. Non-transgenic control tissue A (cortex) and B (hippocampus) show no distinct fluorescence. Dense core plaques are highlighted in the cortex (C) and hippocampus (D) of treated sections from APP/PSEN1 mice. Scale bar = 100 μm. (E) Cortex and (F) Hippocampus sections from brains treated with untargeted (i.e. no XO4) liposomes, showing no binding.

doi:10.1371/journal.pone.0048515.g004

Figure 5. Competition between Chrysamine G (CG) and targeted liposomes for binding sites on Aβ plaques. Brain tissue sections were incubated with 1 μM nanoparticles and increasing concentrations of CG. Scale bar = 100 μm.

doi:10.1371/journal.pone.0048515.g005
targeted nanoparticles follow the same clearance route allowing them access to almost all the plaque deposits along this route. Furthermore, Meyer et al [23] have observed that microvasculature in APP23 Tg mice abruptly ended at amyloid plaques, and that plaque deposits sat near or at the end of truncated vessels. These suggest that the plaques would be well accessible to the long circulating nanoparticles, especially if the surrounding tissue is inflamed.

Figure 10 provides verification that the liposomes are actually transported intact, across the BBB and bind to amyloid plaques. By labeling both the liposomal interior compartment (with Rhodamine) and the bilayer membrane (with XO4), and injecting these liposomes i.v. in transgenic mice, co-localization of the two tracers at amyloid plaque sites can be considered an indication of intact transport of the liposomal particles to the plaques. This is demonstrated in Figure 10A. Figures 10B, 10C and 10D are the corresponding controls, (10B: transgenic mouse treated with XO4 targeted liposomes, with no Rhodamine, 10C: transgenic mouse treated with saline, 10D: non-transgenic mouse treated with Rhodamine-XO4 liposomes). Clearly, amyloid plaques are visible in the XO4 images in 10A and B, with co-localization of the Rhodamine signal in 10A demonstrating that fluorescent Aβ targeted liposomal nanocarriers can cross the BBB and bind to Aβ pathologies in an AD mouse model. Delivery of any exogenous agents to the brain from the vascular compartment is usually hindered by the effectiveness of the BBB in restricting transport to
the CNS. That these particles are able to cross the BBB and label amyloid plaques in as young as 7-month old APP/PSEN1 transgenic mice has multiple implications. Significantly, liposomal nanocarriers have previously been shown to be versatile, safe, and effective delivery vehicles for many drugs ranging from small molecules to proteins (both enzymatic and non-enzymatic) [49]. The fact that these particles can be loaded with CT [36] or MR [37] contrast agent payloads suggests the possibility of using either CT or MR for the imaging of amyloid deposits. Since the particles can carry up to $10^6$ molecules of contrast agent each, they can effectively increase signal by up to a factor of $10^6$ over that of conventional CT or MR agents. Coupled with the exceptional spatial resolution of MRI [37] this agent should allow for the visualization of features at a voxel size of 30 μm, providing superior spatial resolution, allowing for the separation of parenchymal plaques from CAA. Clearly, the contrast developed in such images will result from a balance between the rapid clearance of unbound species and the relatively slow clearance of bound species from the brain. One anticipates that unbound species would clear by the normal mechanisms of CSF transport, dominated by CSF convection in the arachnoid space, driven by carotid pulsation. The other transport mechanisms such as transcytosis and perivascular clearance probably have similar time constants, but also account for far lower total flux. With binding constants in the micromolar range, dissociation is quite likely to occur after bulk clearance takes place, enabling longitudinal imaging. Similarly, the therapeutic payload capacity of stealth liposomes has been extensively demonstrated [49]. We therefore suggest the potential for the use of these particles as drug carriers to the site of amyloid deposits.

Conclusions

This study reports the preparation of Aβ-targeted stealth liposomal nanoparticles using the Aβ-targeted lipid conjugate DSPE-PEG-XO4. These nanoparticles maintain similar binding profiles to Aβ[1-40], as the free XO4 ligand in vitro. They selectively bind to amyloid deposits in brain tissue sections of APP/PSEN1 transgenic mice in vitro. Ex vivo analyses of treated brain tissue show that when injected into these mice, the targeted particles efficiently bind both parenchymal plaques and CAA associated amyloid throughout the brain. In vitro immunohistochemistry, and verified co-localization of both the liposome encapsulate and bilayer membrane components performed on brain tissue sections obtained from treated animals confirmed the ability of the particles to traverse the BBB and bind amyloid-β plaque deposits. A fundamental limitation of this work is the fact that the visualization of liposome localization was done ex vivo, after washing of specimens, a process that will necessarily wash away unbound liposomes, and reduce the background signal. When used in vivo, the imaging will not have this luxury, and it remains to be seen whether the bound liposome signal will be discernible above the unbound background. There are currently two reports of liposomal preparations with affinity to Aβ fibrils in vitro [50,51]. The theme of both reports is to develop Aβ aggregate clearance systems, and not as a delivery system to the sites of amyloid plaque. To the best of our knowledge, the results of the present study are the first report of successful intravenous delivery of Aβ-targeted liposomal nanocarriers to both parenchymal plaques and CAA in a preclinical model of Alzheimer’s disease.

Methods

Chemical Synthesis

General. 2-[2-(2-Boc-aminoethoxy)ethoxy]ethanol (2) was purchased from GInventChem, Inc. and 4-Formyl-2-methoxyphenylboronic acid (9) was purchased from AOBChem, Inc. All other reagents were obtained from Sigma-Aldrich or Acros Organics and used without further purification. Proton nuclear magnetic resonances ($^1$H NMR) were recorded at 300 MHz or 500 MHz on Bruker 300 or 500 NMR spectrometers. Carbon nuclear magnetic resonances ($^{13}$C NMR) were recorded at 75 MHz or 125 MHz on a Bruker 300 or 500 NMR spectrometers respectively. Chemical shifts are reported in parts per million (ppm) from an internal standard acetone (2.05 ppm), chloroform (7.26 ppm), or dimethyl-sulfoxide (2.50 ppm) for $^1$H NMR; and from an internal standard acetone (206.26 ppm), chloroform (77.00 ppm), or dimethylsulfoxide (39.52 ppm) for $^{13}$C NMR. NMR peak multiplicities are denoted as follows: s (singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet), dd (doublet of doublet), tt (triplet of triplet), dd (doublet of doublet of doublet), and m (multiplet). Coupling constants (J) are given in hertz (Hz). High resolution mass spectra (HRMS) were obtained from The Ohio State University Mass Spectrometry and Proteomics Facility. Thin layer chromatography (TLC) was performed on silica gel 60 F$_{254}$ plates from EMD Chemical Inc. and components were visualized by ultraviolet light (254 nm) and/or phosphomolybdic acid,

Figure 8. Targeted liposomes bind amyloid deposits in cerebral amyloid angiopathy in 12-month-old APP/PSEN1 mice. Leptomeningial blood vessel (A) with prominent amyloid deposits. Prominent CAA (B), showing characteristic ring structure, in a large cerebellar blood vessel. Smaller vessels and capillaries (C), similarly affected by CAA, are bound by the particles. Scale bar = 100 μm.

doi:10.1371/journal.pone.0048515.g008

Figure 8. Targeted liposomes bind amyloid deposits in cerebral amyloid angiopathy in 12-month-old APP/PSEN1 mice. Leptomeningial blood vessel (A) with prominent amyloid deposits. Prominent CAA (B), showing characteristic ring structure, in a large cerebellar blood vessel. Smaller vessels and capillaries (C), similarly affected by CAA, are bound by the particles. Scale bar = 100 μm.
20 wt% solution in ethanol. SiliFlash silica gel (230–400 mesh) was used for all column chromatography.

2-[[2-(2-bromoethoxy)ethoxy]-N-Boc-ethanamine (3). To a solution of alcohol 2 (1.00 g, 4.01 mmol) and PPh₃ (1.37 g,
Figure 10. Targeted liposomes bind intact to amyloid plaques when injected \textit{in vivo}. To demonstrate that particles bind intact to amyloid plaque pathology, mice were injected with targeted Rhodamine-loaded liposomes, sacrificed 72 h after injection, and the tissue was examined using fluorescence microscopy. \textbf{A.} Liposomal X04 and Rhodamine signal co-localize in plaques labeled by Rhodamine-loaded targeted liposomes \textbf{B.} Tissue from an APP/PS1 mouse injected with unloaded targeted liposomes shows signal only in the liposomal X04 channel. \textbf{C.} Tissue from a saline-injected APP mouse, \textbf{D.} non-transgenic mouse injected with Rhodamine-loaded X04 targeted liposomes. Scale bar=100 μm. Co-localization of the Rhodamine signal (originating with the encapsulated Rhodamine) and the X04 signal (originating with the X04 ligand on the surface of the liposome) verifies that the two fluorophores are transported to the sites of amyloid deposition simultaneously, suggesting the liposomes are transported to the site intact.

doi:10.1371/journal.pone.0048515.g010
5.21 mmol) in CH₂Cl₂ (20 mL) at 0°C, under positive N₂ pressure, was added a solution of carbontetrachloride (1.73 g, 5.21 mmol) in CH₂Cl₂ (10 mL). The mixture was stirred at 0°C for a further 30 min, after which it was allowed to come to room temperature overnight. The solvent was removed in vacuo to obtain a white paste. Ethyl acetate (10 mL) was added and the resulting mixture shaken vigorously to obtain a white precipitate. This was filtered off and the ensuing filtrate containing the bromine was concentrated and purified by flash column chromatography on silica gel eluted with 25% ethyl acetate/hexanes to obtain previously reported 3 [52] as colorless oil (841 mg, 84% yield).

1H NMR (CDCl₃, 500 MHz) δ 5.17 (s, 2H), 4.59 (s, 2H), 3.48 (s, 3H).

To a stirred mixture of alcohol (6.82 g, 100% yield) which was dissolved in ethanol (30.0 mL). To this was added NaBH₄ protected 4-hydroxybenzaldehyde (6.82 g, 100% yield) which the solvent by rotary evaporation gave the desired MOM-protected 4-hydroxybenzaldehyde (6.82 g, 100% yield) which was used in the next step without further purification.

MOM-protected 4-hydroxybenzaldehyde (3.00 g, 18.06 mmol) was dissolved in ethanol (30.0 mL). To this was added NaBH₄ (704.8 mg, 18.63 mmol) in one portion. The resulting mixture was stirred at ambient temperature for 45 min at which point it was cooled in an ice bath and excess acetone added drop wise to quench unreacted NaBH₄. The solvents were then removed by rotary evaporation and the residue dissolved in ethyl acetate, washed with saturated NH₄Cl solution and brine, and dried over Na₂SO₄. Removal of the solvent by rotary evaporation gave the desired MOM-protected 4-hydroxybenzaldehyde (6.82 g, 100% yield) which was deoxygenated by bubbling N₂ through it for 30 min. It was then poured into brine (100 mL) and the two phases separated. The aqueous phase was then added to a solution of anhydrous K₂CO₃ (11.32 g, 81.87 mmol), followed by MOMCl (3.4 mL, 45.04 mmol). The resulting mixture was stirred for 5 h followed by filtration to remove inorganic salts. Acetone was then stripped from the filtrate on a rotary evaporator and the resulting crude mixture which was purified by chromatography on silica gel column eluted with 20% ethylacetate/hexanes to obtain previously reported 8 [53] as golden flakes (5.31 g, 65% yield, 93:7 E/Z). 1H NMR (CDCl₃, 300 MHz) δ 7.28 (d, J = 8.7 Hz, 2H), 7.05 (d, J = 8.7 Hz, 2H), 5.17 (s, 2H), 4.59 (s, 2H), 3.48 (s, 3H).

(E)-4-(2-iodovinyl)phenol (8). CrCl₂ (12.08 g, 98.26 mmol) was placed in a nitrogen-flushed dry flask and flame-dried under high vacuum. After cooling to room temperature, THF (90 mL) was added and the resulting suspension cooled to 0°C under positive N₂. A mixture of iodide (19.34 g, 49.13 mmol) and 4-hydroxybenzaldehyde (3.00 g, 24.56 mmol) in THF (50 mL) was added and the resulting mixture stirred at 0°C for 3 h. It was then poured into brine (100 mL) and the two phases separated. The aqueous phase was then added to a solution of anhydrous CH₃Cl (3×50 mL) and the combined organic extracts dried (Na₂SO₄), concentrated and chromatographed on silica gel eluted with a mixture of ethyl acetate/hexanes (1:9). Fractions containing the product were concentrated to obtain a white solid which was recrystallized in hexanes to yield previously reported iodide (8) [53] as golden flakes (5.31 g, 65% yield, 93:7 E/Z). 1H NMR (CDCl₃, 300 MHz) δ 7.24 (d, J = 15.0 Hz, 1H), 7.08 (d, J = 8.7 Hz, 2H), 6.75 (d, J = 8.7 Hz, 2H), 6.49 (d, J = 15.0 Hz, 1H); 13C NMR (CDCl₃, 75 MHz) δ 157.11, 144.43, 141.95, 129.86, 127.30, 115.57.

(E)-4-(2-hydroxybenzyl)phenol (9). A mixture of compounds 8, tetrazole (7), and [1,1’-Bis(diphenylphosphino)-ferrocene]dichloropalladium (II) complexed with dichloromethane (794 mg, 2.44 mmol), and [1,1’-Bis(diphenylphosphino)-ferrocene]dichloropalladium (II) complexed with dichloromethane (19.9 mg, 0.02 mmol) in toluene/ethanol/water (4:4:1, 9 mL) was deoxygenated by bubbling N₂ through it for 30 min. It was then heated at 70°C overnight, after which TLC showed complete consumption of the iodide. Upon cooling to ambient temperature, it was diluted with water (5 mL) and extracted with ethylacetate, dried over Na₂SO₄, concentrated, and chromatographed on silica gel column eluted with ethylacetate/hexanes (2:3) to obtain 9 as a pale yellow solid (163.0 mg, 79% yield). 1H NMR (DMSO-d₆, 300 MHz) δ 9.95 (s, 1H), 9.71 (s, 1H), 7.84 (d, J = 7.2 Hz, 1H), 7.47–7.55 (m, 4H), 7.35 (d, J = 16.6 Hz, 1H), 7.24 (d, J = 16.6 Hz, 1H), 6.80 (d, J = 8.4 Hz, 2H), 3.95 (s, 3H); 13C NMR (DMSO-d₆, 75 MHz) δ 192.17, 157.94, 156.40, 153.68, 132.49, 128.02, 126.02, 128.13, 118.33, 115.72, 110.46, 55.72; HRMS cld for C₁₉H₁₄NO₃Na⁺m/z (M+Na) 383.0784, found 383.0785.

(E)-4-[2-(4-bromoacetyl)phenyl]ethoxy)ethoxy)ethoxy]styryl)-3-methoxybenzaldehyde (10). A mixture of compounds 8, tetrazole (7), and 4-formyl-2-methoxyphenyl boronic acid (176.0 mg, 0.98 mmol), C₄H₆CO₂ (794 mg, 2.44 mmol), and Na (11). A mixture of compounds 10 (733 mg, 2.88 mmol), 3 (1.08 g, 3.46 mmol), and anhydrous DMF (20 mL) were placed in a boiling tube, sealed and heated at 70°C for 5 h. Upon cooling to room temperature, the white solid was filtered off. The filtrate was diluted with ethyl acetate, washed (saturated NH₄Cl solution and brine), dried over Na₂SO₄, concentrated, and chromatographed on silica gel eluted with 40% ethyl acetate/hexanes to yield 10 (334.0631). The organic phase was then added to a solution of 8 (96% yield), 9 (93:7 E/Z), 7 (93:7 E/Z), and [1,1′-Bis(diphenylphosphino)-ferrocene]dichloropalladium (II) complexed with dichloromethane (19.9 mg, 0.02 mmol) in toluene/ethanol/water (4:4:1, 9 mL) was deoxygenated by bubbling N₂ through it for 30 min. It was then heated at 70°C overnight, after which TLC showed complete consumption of the iodide. Upon cooling to ambient temperature, it was diluted with water (5 mL) and extracted with ethylacetate, dried over Na₂SO₄, concentrated, and chromatographed on silica gel column eluted with ethylacetate/hexanes (2:3) to obtain 10 as a pale yellow solid (163.0 mg, 79% yield). 1H NMR (DMSO-d₆, 300 MHz) δ 9.95 (s, 1H), 9.71 (s, 1H), 7.84 (d, J = 7.2 Hz, 1H), 7.47–7.55 (m, 4H), 7.35 (d, J = 16.6 Hz, 1H), 7.24 (d, J = 16.6 Hz, 1H), 6.80 (d, J = 8.4 Hz, 2H), 3.95 (s, 3H); 13C NMR (DMSO-d₆, 75 MHz) δ 192.17, 157.94, 156.40, 153.68, 132.49, 128.02, 126.02, 128.13, 118.33, 115.72, 110.46, 55.72; HRMS cld for C₁₉H₁₄NO₃Na⁺m/z (M+Na) 383.0784, found 383.0785.

Delivery of Targeted Liposomes to Amyloid-β
\[ J = 16.5 \text{ Hz}, 1H], 6.95 (d, J = 8.5 \text{ Hz}, 2H), 4.20 (t, J = 4.5 \text{ Hz}, 2H), 3.98 (s, 3H), 3.90 (t, J = 4.5 \text{ Hz}, 2H), 3.75 (s, J = 4.5 \text{ Hz}, 2H), 3.68 (m, 2H), 3.58 (s, J = 5.0 \text{ Hz}, 2H), 3.35 (bs, 2H), 1.46 (s, 9H); ^{13}C \text{ NMR (CDCl}_3, 125 \text{ MHz}) \delta 191.74, 159.10, 157.19, 136.17, 133.56, 132.14, 130.43, 128.96, 122.65, 124.53, 120.38, 112.03, 109.49, 70.94, 70.49, 69.07, 67.63, 55.97, 40.53, 28.56; \text{HRMS clcd for } C_{27}H_{35}NO_{7}Na \text{ m/z 133.12, 132.78, 129.98, 129.79, 129.51, 129.46, 128.63, 127.95, 127.58, 122.69, 121.00, 118.27, 116.62, 110.53, 96.04, 79.56, 72.34, 71.93, 71.65, 71.50, 69.37, 57.03, 56.91, 42.05, 29.60; \text{HRMS clcd for } C_{36}H_{45}NO_{8}Na \text{ m/z 642.3051, found 642.3051.}

**Synthesis of Aβ Fibrils**

Beta-Amyloid$_{1-40}$ peptide was purchased from rPeptide (Bogart, GA). The fibrils were prepared following the protocol outlined by Klunk et al [38]. Aβ$_{1-40}$ was dissolved in PBS, pH 7.4 to a final concentration of 433 μg/ml (100 μM). The solution was stirred using a magnetic stir bar at 700 rpm for 4 days at room temperature to drive the formation of fibrils. The stock solution was aliquoted and stored at −80°C for future use. The stock solutions were stirred thoroughly before removing aliquots for binding assays, to maintain a homogenous suspension of fibrils.

**Binding Affinity of Targeted Liposomes to Synthetic Aβ Fibrils**

Targeted liposomes and XO4 stock solutions were diluted with 10 mM Tris-HCl, pH 7.4 to 500 mM. A small volume of the 100 μM Aβ stock solution was added to the test compounds to achieve a final fibril concentration of 20 μM. This was followed by addition of appropriate concentrations of the non-fluorescent competitor Chrysamine G. The binding mixture was incubated at room temperature for 1 h and then centrifuged for 20 min at 16,400 rpm to separate the fibrils. The precipitate was washed twice with Tris-HCl, and resuspended in the buffer. Fluorescence was measured in a SpectraMax-384 plate reader using excitation and emission wavelengths of 368 nm and 450 nm, respectively.

**Animal Studies**

All animal studies reported in this paper were conducted under study-specific protocols that were specifically approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Houston. The B6.Cg-TgAPPsw/ePSEn1-dE938D30/oJ APP/PSEn1; Jackson Laboratories) mouse line was used in this study. These double transgenic mice express a chimeric mouse/human amyloid precursor protein (Mo/ HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9) both directed to CNS neurons and associated with early-onset Alzheimer’s disease. These mice progressively develop cortical

Delivery of Targeted Liposomes to Amyloid-β

Preparation of Targeted Liposomes

A lipid mixture consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol, 1,2-distearyloxy-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG-2000), and DSPE-PED-3400-XO4 in a molar ratio of 36.5:40:6:3:0:9:5 was dissolved in ethanol (600 μL) and slowly warmed in a water bath to obtain a clear solution. This was then transferred to a histidine/saline buffer, pH 7 (5 mL) at 65°C and allowed to hydrate for 45 min, followed by extrusion on a Lipex thermoline extruder (Northern Lipids Inc., Canada), with five passes through a 200 nm Nuclepore membrane (Waterman, Newton, MA) followed by ten passes through a 100 nm membrane. The resulting preparation was subjected to dialfiltration through a 100,000 MWCO membrane to remove any free floating lipids or unencapsulated materials. Mean particle size was determined by transmission electron microscopy.

**Animal Studies**

All animal studies reported in this paper were conducted under study-specific protocols that were specifically approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Houston. The B6.Cg-TgAPPsw/ePSEn1-dE938D30/oJ APP/PSEn1; Jackson Laboratories) mouse line was used in this study. These double transgenic mice express a chimeric mouse/human amyloid precursor protein (Mo/ HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9) both directed to CNS neurons and associated with early-onset Alzheimer’s disease. These mice progressively develop cortical
and hippocampal Aβ plaques, accompanied by cerebral amyloid angiopathy, in an age-related manner similar to that observed in human patients [54,55,56]. In all animal experiments, 4 mice were used in each test and control group, processed according to specific methods described below. Images shown are representative of each group.

**In vitro Treatment of Mouse Brain Tissue with Targeted Liposomes**

Brain tissue slices from APP/PSEN1 transgenic mice were incubated in a solution of targeted liposomes (1 μM, in 10 mM Tris-HCl, pH 7.4), at room temperature for 1 h. The sections were then washed extensively with Tris-HCl to remove unbound liposomes, mounted with Vectashield media and viewed under a confocal microscope (Olympus IX61 DSU). Images were processed with Neurolucida (Microbrightfield). Brain tissue sections from control animals and young mice with no amyloid plaques, were also processed following similar procedures and stained as described above, to rule out non-specific binding.

**Intravenous Delivery of Targeted Liposomes to Cortical and Hippocampal Plaques in APP/PSEN1 Transgenic Mice**

APP/PSEN1 transgenic mice were anesthetized by isoflurane inhalation. Targeted liposomes were then injected via the tail vein, at a lipid dose of 135 μmol/kg. The animals were euthanized 72 h post-injection and the brain excised. The brain was fixed in 10% formalin and stored in 30% sucrose prior to sectioning. A cryotome (Leica) was used to obtain 30 μm coronal sections of the whole brain. The tissue sections were transferred into phosphate-buffered saline, pH 7, and stored at 4°C. The sections were then mounted with Vectashield media and viewed under an Olympus IX61 DSU microscope. Images were processed with Neurolucida (Microbrightfield). Brain tissue sections from control animals and young mice with no amyloid plaques, were also processed following similar procedures and stained as described above, to rule out non-specific binding.

**Ex vivo Liposome Co-localization Study**

Rhodamine was encapsulated into XO4-targeted liposomes by the passive loading method, at a concentration of 10 mM as described in the liposome preparation section above. 72 h after intravenous injection in anesthetized mice, the animals were sacrificed, the brains fixed in 4% paraformaldehyde for 48 h at 4°C, transferred to 30% sucrose in 1X-PBS at 4°C until the tissue sank (usually about 72 h). The tissue was then embedded in OCT compound (Sakura Finetek, Torrance CA) and stored at −80°C until serial sectioning. Sections were cut at 30 μm thickness, and stored at 4°C in PBS until mounted. The sections were then mounted with Vectashield media and viewed under an Olympus IX61 DSU microscope. Imaging was conducted in two channels using a 20X objective. Liposomal MeXO4 was imaged using a Brightline DAPI-506B-OMF filter set (Semrock, Rochester, NY); Similar to XO4, the labeled liposomes exhibit a peak fluorescence at 430 nm.

**Supporting Information**

**Information S1** ¹H NMR and ¹³C NMR spectra of all new compounds; ¹H NMR and MALDI mass analysis of conjugate; TEM image of liposomes and liposome stability test data. (PDF)

**Author Contributions**

Conceived and designed the experiments: EAT ID MS SCC JLE AA. Performed the experiments: EAT ID MS RCB LS JB HP RK GE JLE. Analyzed the data: EAT ID MS JLE AA. Contributed reagents/materials/analysis tools: JLE AA. Wrote the paper: EAT ID MS JLE AA.
11. Armstrong RA (1999) Do β-Amyloid (Aβ) Deposits in Patients with Alzheimer’s Disease and Down’s Syndrome Grow According to the Log-Normal Model? Neurosci Lett 261: 97–100.

12. Bussière T, Bzd F, Barbour R, Grajeda H, Glade T, et al. (2004) Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Mice and Effect of Aβ Immunotherapy on their Clearance. Am J Pathol 163: 987–995.

13. Fala JC (2007) Mechanism of Amyloid Plaque Pathogenesis. Acta Neuropathol 114: 531–571.

14. Drzezga A (2000) Basic Pathologies of Neurodegenerative Dementias and Their Relevance for State-of-the-Art Molecular Imaging. Eur J Med Mol Imaging 35: 84–91.

15. Pike KE, Gavrilouk V, Villenave VL, Ng S, Moss SA, et al. (2007) β-Amyloid Imaging and Memory in Non-Demented Individuals: Evidence for Preclinical Alzheimer’s Disease. Brain 130: 2837–2844.

16. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Arch Neurol 65: 1309–1517.

17. Reitan EM, Chen K, Liu X, Bandy D, Yu M, et al. (2009) Fibriil Amyloid-β Burden in Cognitively Normal People at 3 Levels of Genetic Risk for Alzheimer Disease. Proc Natl Acad Sci USA 106: 6829–6825.

18. Iadecola C (2004) Neurovascular Regulation in the Normal Brain and in Alzheimer’s Disease. Nat Rev Neurosci 3: 347–360.

19. Zlokovic BV (2005) Neurovascular Mechanisms of Alzheimer’s Neurodegeneration. Trends Neurosci 28: 202–208.

20. Benaroche E (2007) Neurovascular Unit Dysfunction: a Vascular Component of Alzheimer’s Disease. Neurology 68: 1730–1732.

21. Zipser BD, Johanson CE, Gonzales L, Berzin TM, Tavares R, et al. (2007) Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer’s Disease. Proc Natl Acad Sci U. S. A 104: 3587–3592.

22. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, et al. (2005) Microvascular Injury and Blood-Brain Barrier Leakage in Alzheimer’s Disease. Neurobiol Aging 28: 977–986.

23. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, et al. (2005) Core-Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer’s Disease. Proc Natl Acad Sci U. S. A 102: 202–208.

24. Meyer EP, Umlmann-Scaller A, Staufnab M, Krucker T (2008) Altered Morphology and 3D Architecture of Brain Vascularization in a Mouse Model of Alzheimer’s Disease. Proc Natl Acad Sci U. S. A 105: 13587–13592.

25. Paris D, Humphrey J, Quadros A, Patel N, Creacisennti R, et al. (2003) Vasoinactive Effects of Aβ in Isolated Human Cerebrovessels and in a Transgenic Mouse Model of Alzheimer’s Disease: Role of Inflammation. NeuroNeurol 25: 450–651.

26. Cullen KM, Koci Z, Stone J (2006) Microvascular Pathology in the Aging Human Brain: Evidence that Senile Plaques are Sites of Microhaemorrhage. Neurobiol. Aging 27: 1786–1796.

27. Biron KE, Dickstein DL, Gopaul R, Jefferies WA (2011) Amyloid Triggers Microvascular Injury and Blood-Brain Barrier Leakage in Alzheimer’s Disease. J Neuropathol Exp Neurol 69: 1351–1371.

28. Lockhart A (2006) Imaging Alzheimer’s Disease Pathology: One Target Many Ligands. Drug Discovery Today 11: 1093–1099.

29. Mathis CA, Wang Y, Klink WE (2004) Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. Curr Pharm Design 10: 1495–1502.

30. Takai K, Nitta K, Urito K (1986) Simple and Selective Method for Aldehydes (RCHO) –(E)-Haloketones (RCH=C=CHR). Conversion by Means of a Hydroxyl-Chromous Chloride System. J Am Chem Soc 108: 7408–7411.

31. Fiala JC (2007) Mechanism of Amyloid Plaque Pathogenesis. Acta Neuropathol 114: 337–341.

32. Weller RO, Djuanda E, Yow H-Y, Carare RO (2009) Lymphatic Drainage of the Brain and the Pathophysiology of Neurological Disease. Acta Neuropathol 114: 1643–1654.

33. Herzig MC, Van Nostrand WE, Jucker M (2006) Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Mice and Effect of Aβ Immunotherapy on their Clearance. Am J Pathol 163: 987–995.

34. Abbott NJ (2004) Evidence for Bulk Flow of Brain Interstitial Fluid: Significance for Physiology and Pathology. Neurosoc Int 45: 545–552.

35. Nicoll JAR, Yamasda M, Frackowiak J, Mazur-Kolecia B, Weller RO (2004) Cerebral Amyloid Angiopathy Plays a Direct Role in the Pathogenesis of Alzheimer’s Disease. Pro-CFAA Position Statement. Neurobiol Aging 25: 599–597.

36. Mukundan S, Ghaghada KB, Radea CT, Kao CY, Heihland LW, et al. (2006) A Liposomal Nanoscale Contrast Agent for Preclinical CT in Mice. ARJ Am J Roentgenol 186: 300–307.

37. Ghaghada KB, Ravoori M, Sahapathy D, Bankom J, Kundra V, et al. (2009) Novel Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging. PLoS ONE 4(10): e7628.

38. Lockhart A, Ye L, Judl DB, Merritt AT, Low P, et al. (2003) Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer’s Disease PET Imaging Agents on Beta-Amyloid Peptide Fibrils. J Biol Chem 280: 7677–7684.

39. Zhang W, Oya S, Kung MP, Hu C, Maier DL, et al. (2005) F-18 Silbexnes as PET Imaging Agents for Detecting β-Amyloid Plaques in the Brain. J Med Chem 48: 5980–5988.

40. Amatuzo T, Morikawa I, Inushishi T, Urushimata H, Taguchi I, et al. (2009) Trifluoromethoxy-Benzylated Ligands Improve Amyloid Detection in the Brain Using 19F Magnetic Resonance Imaging. Neurosci Res 63: 76–81.

41. Blakemore FL, Cole VJ, Koci Z, M jor BA (1998) Stereoselective Synthesis of 2,2,3,3,4,4-Hexakis(4-O-Tosyl-3,5-Diisopropylphenyl)pyrrole. J Chem Soc Chem Commun : 866–867.

42. Takai K, Nitta K, Urito K (1986) Simple and Selective Method for Aldehydes (RCHO) –(E)-Haloketones (RCH=C=CHR). Conversion by Means of a Hydroxyl-Chromous Chloride System. J Am Chem Soc 108: 7408–7411.

43. Ghaghada KB, Radea CT, Kao CY, Heihland LW, et al. (2006) A Liposomal Nanoscale Contrast Agent for Preclinical CT in Mice. ARJ Am J Roentgenol 186: 300–307.

44. Ghaghada KB, Raveo M, Sahapathy D, Bankom J, Kundra V, et al. (2009) Novel Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging. PLoS ONE 4(10): e7628.

45. Klink WE, Backsak BJ, Mathis CA, Kajfasz ST, Mclellan ME, et al. (2002) Imaging β-Amyloid Plaques in Living Transgenic Mice with Multiphotonmicroscopy and a New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging. PLoS ONE 4(10): e7628.

46. Blakemore FL, Cole VJ, Koczi Z, Morley AA (1998) Stereoselective Synthesis of Trans-1,2,3-Trisubstituted Alkenes Based on the Condensation of Aldehydes with Metallated 1-Phenyl-1H-Tetrazol-5-yl Sulfoxides. Synlett: 26–28.

47. Lockhart A (2006) Imaging Alzheimer’s Disease Pathology: One Target Many Ligands. Drug Discovery Today 11: 1093–1099.

48. Mathis CA, Wang Y, Klink WE (2004) Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. Curr Pharm Design 10: 1495–1502.

49. Blakemore FL, Cole VJ, Koci Z, Morley AA (1998) Stereoselective Synthesis of Trans-1,2,3-Trisubstituted Alkenes Based on the Condensation of Aldehydes with Metallated 1-Phenyl-1H-Tetrazol-5-yl Sulfoxides. Synlett: 26–28.

50. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-Type Phenotype in Transgenic Mice Carrying both Mutant Amyloid Precursor Protein and Presenilin 1 Transgenes. Nat Med 4: 97–100.

51. Jankowsky JL, Shait HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of Multiple Transgenes in Mouse CNS: A Comparison of Strategies. Biomol Eng 17: 157–163.